COPENHAGEN (Reuters) - Shares in Denmark’s biotech firm Pharmexa rocketed on Wednesday after it announced positive test data of its breast cancer vaccine and repeated it would start further trials later this year.
“The data show that the vaccine is well tolerated and safe and that it induces significant HER-2 specific antibodies in breast cancer patients,” the company said in a statement.
Pharmexa said it would continue developing the vaccine through a phase II test in the second half of this year and expected preliminary results from this study in mid-2006.
Shares in Pharmexa jumped 10 percent to a one-week high of 31 crowns by 1025 GMT, outpacing Copenhagen’s blue-chip KFX-index, which was flat.
Breast cancer is the most prevalent form of cancer among women and the single most common cause of death among women in Denmark. Primary treatment in most Western countries consists of surgery combined with chemotherapy and radiation therapy.
MeSH Headings:Recombinant Proteins: Vaccines, Synthetic: Cancer VaccinesCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
